Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial.

Maria Vittoria Dieci, Davide Massa, Elisa Gasparini et al. Jun 01, 2026 pp. 1010-1010 10.1200/jco.2026.44.16_suppl.1010

1010 Background: Circadian rhythms regulate immune functions, and morning (AM) administration of immunotherapy (IO) is ass...

Impact of U.S. most-favored-nation (MFN) drug pricing on global oncology access.

Ariel Hammerman, Christina Anagnostopoulou, Ilan Kochba et al. Jun 01, 2026 pp. 11056-11056 10.1200/jco.2026.44.16_suppl.11056

11056 Background: U.S. cancer drug prices substantially exceed those in other OECD countries. In May 2025, a U.S. Presiden...

Construction and validation of a prognostic risk model for lung adenocarcinoma based on pyroptosis and necroptosis-related genes.

Beilei Gong Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20034

e20034 Background: Lung cancer is a leading cause of cancer-related deaths worldwide, and lung adenocarcinoma (LUAD) is th...

First-in-human phase I, open-label, multicenter study of HJ-004, a novel EGFR-PROTAC degrader, in patients with advanced <i>EGFR</i> -mutated non–small cell lung cancer.

Xinru Chen, Caicun Zhou, Li Zeng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8678

TPS8678 Background: Despite remarkable progress with 1 st - to 3...

Risk of gastrointestinal (GI) immune-related adverse events (irAEs): Real-world experience.

Muaz Alsabbagh Alchirazi, Moaath Khader Mustafa Ali, Emily Craig Zabor et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23410

e23410 Background: Immune checkpoint inhibitors (ICI) improve survival across solid tumors but can cause gastrointestinal...

Lisocabtagene maraleucel (liso-cel) as first-line (1L) therapy for transplant-ineligible patients (pt) with primary central nervous system lymphoma (PCNSL): The CAROLYN study.

Allison Marie Winter, Michael Scordo, Caroline Houillier et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps7097

TPS7097 Background: Treatment of PCNSL is based on high-dose methotrexate (HD-MTX) induction chemotherapy, followed by con...

Precision risk stratification for lung cancer in COPD: Evidence from the All of Us Program.

Muhammad Rafiqul Islam, Syeda Masuma Siddiqua, Mohammad Hasan Shahriar et al. Jun 01, 2026 pp. 10537-10537 10.1200/jco.2026.44.16_suppl.10537

10537 Background: Chronic obstructive pulmonary disease (COPD) is a well-established independent risk factor for lung canc...

Alzheimer’s biomarkers in oncology: The impact of cancer treatment on neurodegenerative diagnostic disparities across populations.

Ashvath Arumugam Pillai, Suchita Mylavarapu, Gaurav Kansal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14048

e14048 Background: The intersection of oncology and neurodegenerative disorders has illuminated complex interactions exist...

Real-world utilization of a patient-centric symptom management guide for metastatic breast cancer.

Victoria E. Barghout, Laura Medina, Rebecca Best et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23403

e23403 Background: Metastatic breast cancer (MBC) and its treatments are associated with significant symptom burden that c...

Clinico-genomic landscape of Indian gallbladder cancer: Actionable alterations and opportunities for precision therapy.

Amol Patel, Vineet Govinda Gupta, Viraj Lavingia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16231

e16231 Background: Gallbladder carcinomas (GBC) are the predominant biliary tract malignancies with marked geographic vari...

Comparative transcriptomic analysis of chemotherapy-naive and post-chemotherapy germ cell tumors.

Michal Mego, Katarina Kalavska, Georgina Kolnikova et al. Jun 01, 2026 pp. 5026-5026 10.1200/jco.2026.44.16_suppl.5026

5026 Background: Cisplatin-based chemotherapy is highly effective in testicular germ cell tumors (GCTs); however, the pres...

Targeted combination therapies for untreated chronic lymphocytic leukemia: A network meta-analysis of randomized trials.

Owais Gul, Taimoor Hassan, FNU Sawaira et al. Jun 01, 2026 pp. 7048-7048 10.1200/jco.2026.44.16_suppl.7048

7048 Background: Treatment options for previously untreated chronic lymphocytic leukemia (CLL) have expanded to include bo...

A structured patient advocacy–led communication model to improve awareness, trust, and access to oncology clinical trials in Brazil.

Roberto Jun Arai, Luciana Papaleo Pereira, Heloisa Resende et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13505

e13505 Background: In low- and middle-income countries (LMICs) like Brazil, participation in oncology clinical trials is h...

Real-world outcomes from 3D-PREDICT glioma chemosensitivity testing of primary CNS tumors.

Aidan Jones, Yazmin Odia, Lydia Hodgson et al. Jun 01, 2026 pp. 2060-2060 10.1200/jco.2026.44.16_suppl.2060

2060 Background: 3D-Predict Glioma is an ex vivo chemosensitivity assay that predi...

Leveraging real-world genomic data to characterize immunotherapy response in cancers with germline <i>CHEK2</i> cancer risk variants.

Alok Swaroop, Michelle Weitz, Adam Dugan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22643

e22643 Background: CHK2 is a DNA damage response (DDR) protein critical for maintaining genomic stability. Germline...

Safety and efficacy of asciminib in veterans with chronic myeloid leukemia.

Omar Shukri Yaghi, Puneet Gill, Jacqueline Rose et al. Jun 01, 2026 pp. 6591-6591 10.1200/jco.2026.44.16_suppl.6591

6591 Background: Asciminib was approved for use in previously treated patients with chronic myeloid leukemia (CML) in 2021...

Palliative quad-shot radiation therapy in combination with low dose systemic treatment in advanced head and neck cancer.

Abdul Mateen, Allah Rakha Adil, Famya Abdullah Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18024

e18024 Background: Head and neck cancer (HNC) is one of the most common cancers in Pakistan. Advanced stage is the most co...

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.

Kelvin K. Chan, Ryan W. Chu, Matthew C. Cheung et al. Jun 01, 2026 pp. 3507-3507 10.1200/jco.2026.44.16_suppl.3507

3507 Background: The phase III CHALLENGE trial (CCTG CO.21) demonstrated improved disease-free and overall survival with a...

Timing of telepalliative care and end-of-life outcomes in advanced cancer: A multicenter retrospective cohort study.

Alexandra Mendes Barreto Arantes, Flavia Santos Dumont Sorice, Mariane Castro et al. Jun 01, 2026 pp. 1518-1518 10.1200/jco.2026.44.16_suppl.1518

1518 Background: Telemedicine has become an integral component of palliative care delivery; however, its impact on end-of-...

Rapid multi-task intraoperative diagnosis of lung cancer via deep neural network-driven label-free femtosecond laser imaging (FLI).

Yin Li, Yunlong Wang, Tao Pan et al. Jun 01, 2026 pp. 8019-8019 10.1200/jco.2026.44.16_suppl.8019

8019 Background: Rapid and accurate intraoperative pathological diagnosis is critical for guiding surgical margins and pre...

The early-onset paradox of gastric cancer: Assessment of geographic clustering, biology, treatment, and outcomes.

Pranati Dharmesh Shah, Dani Ran Castillo, Derek Tai et al. Jun 01, 2026 pp. 4088-4088 10.1200/jco.2026.44.16_suppl.4088

4088 Background: Early-onset gastric cancer (EOGC), defined as diagnosis before age 45, represents an increasingly recogni...

Incidence of colorectal cancer in renal transplant recipients compared with the general population and inflammatory bowel disease: A population-based real-world cohort study.

Mohammed Abdalkarim, Mamtha Balla, Thaer Alhroob et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15707

e15707 Background: Chronic immunosuppression following renal transplantation is associated with an increased risk of malig...

GLP-1 receptor expression in a molecularly characterized cohort of endometrial carcinoma: Results from the GEICO 163-T/SPECTRUM study.

Carlos González-Merino, Alfonso Cortes-Salgado, Esther Moreno et al. Jun 01, 2026 pp. 5625-5625 10.1200/jco.2026.44.16_suppl.5625

5625 Background: The glucagon-like peptide-1 receptor (GLP-1R) plays a central role in metabolic, and hormonal signaling a...

Efficacy and safety of neoadjuvant therapy in resectable pancreatic cancer: Updated systematic review and meta-analysis of RCTs.

Ahsan Ali Khan, Mohammad Dawar Zahid, Mazhar Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16458

e16458 Background: The clinical value of neoadjuvant therapy (NAT) for resectable pancreatic ductal adenocarcinoma remains...

Nivolumab and Ipilimumab (NIVO IPI) as first-line (1L) treatment for patients with metastatic renal-cell carcinoma (mRCC): A real-world benchmarking analysis from the International mRCC Database Consortium (IMDC).

Heber Tomas Reyes-Garcia, Elio Ibrahim, Connor Wells et al. Jun 01, 2026 pp. 4549-4549 10.1200/jco.2026.44.16_suppl.4549

4549 Background: NIVO IPI has demonstrated durable overall survival (OS) benefit with long-term follow-up in patients with...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page